{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:25:23Z","timestamp":1777631123789,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Tenofovir alafenamide fumarate has been used in late pregnancy; however, no data exist regarding its safety and effectiveness in early and middle pregnancy for mothers with hepatitis B virus infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To design a prospective study to investigate the efficacy and safety of TAF in pregnant women with chronic HBV infection during early-middle pregnancy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Pregnant women with active chronic hepatitis B who received tenofovir alafenamide fumarate during early and middle pregnancy were enrolled and followed up until 6 months postpartum. Infants received immunoprophylaxis. The primary endpoint was the safety of mothers and infants. The secondary endpoints were maternal hepatitis B virus DNA reduction at delivery and mother-to-child transmission rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 98 mothers enrolled, 31 initiated tenofovir alafenamide fumarate in early pregnancy, and 57 in middle pregnancy. The mean (\u00b1 standard deviation) age was 29.00 (\u00b13.81) years. At delivery, 100% (98\/98) of the mothers achieved hepatitis B virus DNA levels &amp;lt;200,000 IU\/L. Ninety-eight infants were born, and none had congenital defects or malformations. All infants received hepatitis B virus immunoprophylaxis. The mother-to-child transmission rate was 0%. Growth parameters including body weight, height, and head circumference were comparable to the national standards for physical development. No severe adverse effects were reported in either mothers or infants. No severe liver function damage occurred in any of the mothers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Initiating tenofovir alafenamide fumarate in early and middle pregnancy appears safe for both mothers and infants, and it is effective for controlling maternal disease as well as interrupting mother-to-child transmission.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2021.796901","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T06:33:50Z","timestamp":1642401230000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B"],"prefix":"10.3389","volume":"8","author":[{"given":"Ruochan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyuan","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuegong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41575-020-00361-w","article-title":"Viral hepatitis and pregnancy","volume":"18","author":"Terrault","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.cld.2010.09.007","article-title":"Pregnancy-related liver diseases","volume":"15","author":"Pan","year":"2011","journal-title":"Clin Liver Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.cgh.2011.10.041","article-title":"An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus","volume":"10","author":"Pan","year":"2012","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/apt.14577","article-title":"An expert consensus for the management of chronic hepatitis B in Asian Americans","volume":"47","author":"Tong","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3760\/cma.j.issn.1007-3418.2015.12.002","article-title":"[The guideline of prevention and treatment for chronic hepatitis B: a 2015 update]","volume":"23","author":"Hou","year":"2015","journal-title":"Zhonghua Gan Zang Bing Za Zhi."},{"key":"B8","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3760\/cma.j.issn.1007-3418.2019.12.007","article-title":"[The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]","volume":"27","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi."},{"key":"B9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00431-019-03481-x","article-title":"Safety of tenofovir during pregnancy: early growth outcomes and hematologic side effects in HIV-exposed uninfected infants","volume":"179","author":"Seidel","year":"2020","journal-title":"Eur J Pediatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1093\/cid\/civ437","article-title":"Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy","volume":"61","author":"Siberry","year":"2015","journal-title":"Clin Infect Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e3324","DOI":"10.1093\/cid\/ciaa1939","article-title":"Tenofovir alafenamide to prevent perinatal hepatitis B transmission: a multicenter, prospective, observational study","volume":"73","author":"Zeng","year":"2021","journal-title":"Clin Infect Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/apt.16043","article-title":"Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study","volume":"52","author":"Ding","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/hep.23061","article-title":"Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B","volume":"50","author":"Toy","year":"2009","journal-title":"Hepatology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12876-017-0608-7","article-title":"Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission","volume":"17","author":"Sun","year":"2017","journal-title":"BMC Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.cgh.2013.04.026","article-title":"Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants","volume":"11","author":"Pan","year":"2013","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent hepatitis B transmission in mothers with high viral load","volume":"374","author":"Pan","year":"2016","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3760\/cma.j.issn.0578-1310.2018.03.008","article-title":"[A national survey on physical growth and development of children under seven years of age in nine cities of China in 2015]","volume":"56","year":"2018","journal-title":"Zhonghua Er Ke Za Zhi."},{"key":"B21","doi-asserted-by":"publisher","first-page":"701061","DOI":"10.3389\/fmed.2021.701061","article-title":"Suboptimal response to tenofovir alafenamide in two patients with HBeAg-positive hepatitis B: a case report","volume":"8","author":"Chen","year":"2021","journal-title":"Front Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","article-title":"Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)","volume":"119","author":"De Clercq","year":"2016","journal-title":"Biochem Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00535-020-01698-4","article-title":"An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia","volume":"55","author":"Charlton","year":"2020","journal-title":"J Gastroenterol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12072-020-10026-0","article-title":"Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy: systematic review and network meta-analysis","volume":"14","author":"Wu","year":"2020","journal-title":"Hepatol Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S1473-3099(20)30586-7","article-title":"Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis","volume":"21","author":"Funk","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/jvh.12788","article-title":"Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother-to-child transmission of hepatitis B virus","volume":"24","author":"Yi","year":"2017","journal-title":"J Viral Hepat."},{"key":"B28","doi-asserted-by":"publisher","first-page":"E181","DOI":"10.1111\/hepr.12525","article-title":"Efficacy and safety of telbivudine in different trimesters of pregnancy with high viremia for interrupting perinatal transmission of hepatitis B virus","volume":"46","author":"Liu","year":"2016","journal-title":"Hepatol Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s12072-017-9839-5","article-title":"Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B","volume":"12","author":"He","year":"2018","journal-title":"Hepatol Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jhep.2013.02.015","article-title":"Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention","volume":"59","author":"Wen","year":"2013","journal-title":"J Hepatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/apt.15064","article-title":"Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load","volume":"49","author":"Wang","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa1708131","article-title":"Tenofovir versus placebo to prevent perinatal transmission of hepatitis B","volume":"378","author":"Jourdain","year":"2018","journal-title":"N Engl J Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.796901\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T06:33:55Z","timestamp":1642401235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.796901\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":32,"alternative-id":["10.3389\/fmed.2021.796901"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.796901","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"article-number":"796901"}}